Trisail Medical, a spin-off from the National Heart Centre Singapore, is developing the world's simplest and fastest transcatheter medical device to treat tricuspid regurgitation, a heart valve disease affecting >60 million people globally. The company has strong pre-clinical safety data and is raising Series A financing to complete First-in-Human studies. We welcome potential investors and collaborators who wish to learn more about our technology and company to reach out and discuss the opportunity.
Trisail Medical is developing a novel transcatheter tricuspid valve repair device. We welcome partners with interest in cardiac implant/heart valve area. Opportunity for joint product development, testing,clinical development, grants funding & licensing.